Patent · US Active

Imidazole derivatives for the treatment of gastrointestinal disorders

US7745474B2 · kind B2 · utility

0Cited by

6References

29Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Udo Bauer · Achern, DE
Wayne Brailsford · Timrå, SE
Linda Gustafsson · Timrå, SE
Tor Svensson · Timrå, SE
Maria Saxin · Timrå, SE

Key dates

Filing date	Dec 21, 2006
Grant date	Jun 29, 2010
Priority date	—
Expiry date	Jan 28, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D405/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3 and Y are as defined in the description. For example, R1 may be phenyl, R2 may be dimethylamino, R3 may be alkoxy and Y may be a thioylamino- or methyl eneamino- linked substitutuent containing an aryl group.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.